STAT

RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

Will Makary's FDA voucher program survive? RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news

Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program

Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program

“I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.”

How living and practicing medicine abroad complicated my beliefs about universal health care systems “I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.”

https://trib.al/SPSDbbQ

AI titans push Congress for DNA safeguards Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout

In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.

Utah Medical Board scolded for going rogue with AI criticism In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.

The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

Supreme Court backs generic drugmaker in 'skinny labeling' case The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.

Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.

HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.

What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.

What happens at a longevity festival? What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.

The White House has used the program to reward companies that help its political goals.

Drug companies, patient groups urge FDA to pause commissioner’s voucher program The White House has used the program to reward companies that help its political goals.

Why did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."

What RevMed's pancreatic cancer drug meant for one patient Why did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."